Takaki, K.; Nakano, M.; Fukumori, K.; Yano, Y.; Zaizen, Y.; Niizeki, T.; Kuwaki, K.; Fukahori, M.; Sakaue, T.; Yoshimura, S.;
et al. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. J. Clin. Med. 2022, 11, 1483.
https://doi.org/10.3390/jcm11061483
AMA Style
Takaki K, Nakano M, Fukumori K, Yano Y, Zaizen Y, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S,
et al. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. Journal of Clinical Medicine. 2022; 11(6):1483.
https://doi.org/10.3390/jcm11061483
Chicago/Turabian Style
Takaki, Kota, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Yuki Zaizen, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura,
and et al. 2022. "Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis" Journal of Clinical Medicine 11, no. 6: 1483.
https://doi.org/10.3390/jcm11061483
APA Style
Takaki, K., Nakano, M., Fukumori, K., Yano, Y., Zaizen, Y., Niizeki, T., Kuwaki, K., Fukahori, M., Sakaue, T., Yoshimura, S., Nakazaki, M., & Torimura, T.
(2022). Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. Journal of Clinical Medicine, 11(6), 1483.
https://doi.org/10.3390/jcm11061483
